

Computational Drug Discovery


Marina Sirota, PhD

Assistant Professor





Leveraging Computation to Understand Health and Disease Across the Lifespan...



Computational Drug Repurposing

Target based drug repurposing

– Genetics

- Disease based drug repurposing
 - Clinical data, molecular data
- Molecular modeling approaches
 - Docking-based drug repositioning
- Network approaches and global signature based approaches
 - "one drug one target one disease" is not sufficient for complex disease

Problem Statement


Can we use public data to systematically predict relationships between drugs and diseases?



Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ. Discovery and Validation of Drug Indications Using Compendia of Public Gene Expression Data. Science Translational Medicine. Aug 2011.

Problem Statement

Can we use public data to systematically predict relationships between drugs and diseases?



Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ. Discovery and Validation of Drug Indications Using Compendia of Public Gene Expression Data. Science Translational Medicine. Aug 2011.

Data Sources




- Publicly available gene
 expression repository
 - Platforms 17,214
 - Samples 2,066,217
 - Series 84,224
- There are numerous
 experiments dealing with
 disease




- Collection of expression data from cultured human cells
- Orig: 453 exprs of 164 drugs
- Now: 6,000 exprs, 1000+ drugs
- Covers broad range of effects
 - FDA approved drugs
 - Non drug bioactive small molecules

Barrett et al. NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res. 2009. Lamb et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006.




Computational Pipeline





Drug-Disease Relationships




Crohn's Disease

- An inflammatory disease of the intestines that has an autoimmune component
- Affects 500,000 people in North America
- No known pharmaceutical cure
- Current solutions:
 - Reduce inflammation with antiinflammatory drugs and corticosteroids (prednisone)
 - Bad side effects
 - Surgical solutions




Therapeutic Predictions for Crohn's Disease




Topiramate – An Anti-Seizure Drug

- Suppresses the rapid and excessive firing of neurons that start a seizure
- Enhances GABA-activation
- Used to treat epilepsy, bipolar disorder
- Antidepressant
- Investigated as potential treatment for obesity and type II diabetes



Topiramate and Crohn's




Genes that are up-regulated by the drug are down-regulated in the disease

Genes that are down-regulated by the drug are up-regulated in the disease

Animal Model for Crohn's

- TNBS (trinitrobenzene sulfonic acid) + ethanol induced rats:
 - Excellent and reproducible experimental model for Inflammatory Bowel Disease (Crohn's and Ulcerative Colitis)








TNBS Induced


Two Follow-up Validation Studies

- 48 rats each 4 groups of 12 rats
 - Healthy Controls
 - TNBS + Vehicle
 - TNBS + Prednisolone
 - TNBS + Topiramate
- 7 days
- Clinical Signs, Pathology Score, Histology
- Endoscopy Images




mdbiosciences






Drug-Disease Signature




Application to Dermatomyositis

- Dermatomyositis (DM) is a systemic autoimmune disease affecting the skin
- Often painful and disfiguring and cause significant impairment in quality of life for patients
- Used a combination of a targeted and signature approach



DrugBank – Target-based Connectivity Map –Expression-based


Cho HG, Fiorentino D, Lewis M, **Sirota M***, Sarin KY*. Identification of alpha-adrenergic agonists as potential therapeutic agents for dermatomyositis through drug-repurposing using public expression datasets. J Invest Dermatol. 2016 Mar 11. pii: S0022-202X(16)30867-3. doi: 10.1016/j.jid.2016.03.001.



Oxymetazoline for DM Treatment

CMap Drug-Disease Score 13 Final Therapeutic Candidate				Predicted Upstream Regulators Affected by Oxymetazoline				
-1.000 - Therapeutic effect	-0.329 -0.329 -0.329	Afatinib Erlotinib' Gefitinib	ì /	Target		cted by Oxyme		÷
	-0.329	Lapatinib		Gene Symbol	Target Molecule Type	Drug Effect	DM Signature	P-value for DM Signature
	-0.329	Vandetanib		ATM	Kinase	Down	Up	0.0135
	-0.281	Vinblastine		FLI1	Transcription Regulator	Down	Up	0.0493
	-0.219	Oxymetazoline		IFIH1	Enzyme	Down	Up	0.00106
	-0.195	Abciximab						
		N-Acetyl-D		KRAS	Enzyme	Up	Down	0.0122
	-0.134 -0.122	glucosamine Alefacept		SKP2	Other	Down	Up	0.00279
	-0.122	Efalizumab		STAT1	Transcription Regulator	Down	Up	1.83E-23
0 – No effect	-0.122 -0.085	Muromonab Lidocaine'		YWHAZ	Enzyme	Down	Up	0.045
	0.124	Minocycline						
	0.220	Trifluride						
	0.253	Lithium						
	0.261 0.261	Arsenic trioxide Bortezomib						
	0.336	Trimethoprim						
	0.397	Pemetrexed						
	0.397	Pralatrexate						
1 000 Advance offered	0.397	Raltitrexed						
+1.000 - Adverse effect	0.791	Leucovorin'						


- Selective alpha-1 agonist and partial alpha-2 agonist
- Good safety profile for topical forms for rosasea
- Brimonidine, another member of the alpha-2 agonist class available as a gel was tested in the clinic




RESEARCH ARTICLE

DRUG DISCOVERY

Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data



Precision Medicine Approach to Drug Repurposing: Alzheimer's Disease



UCSF Electronic Medical Records (EMR)

- Time span: 2012 today
- Number of patients: 922,59
- Data included:
 - Allergies
 - Diagnosis
 - Encounters
 - Immunizations
 - Lab tests
 - Medications orders
 - Procedure orders
 - Vitals
 - Imaging


















SEARCH 12 MILLION PATIENT RECORDS

- The UC ReX Data Explorer enables search of 12 million de-identified patient records from the 5 UC medical centers with one query
- Complete NIH targeted Enrollment Tables by providing counts of eligible patients by gender, race and ethnicity
- ✓ Increase cohort identification for the study of rare diseases
- Expand your study from a single to a multi-site proposal
- Obtain coordinated data provisioning support through UC ReX

UC HEALTH

Spotlight News Profile Issues Did you know? In the media Impact




UCSF Medical Center at Mission Bay opens Large-scale transport completed with support of city of San Francisco agencies. (CLICK IMAGE TO VIEW)





Big Data -> Precision Medicine



"Doctors have always recognized that every patient is unique, and doctors have always tried to tailor their treatments as best they can to individuals. You can match a blood transfusion to a blood type — that was an important discovery. What if matching a cancer cure to our genetic code was just as easy, just as standard? What if figuring out the right dose of medicine was as simple as taking our temperature?"

- President Obama, January 30, 2015

Acknowledgements

My Group Brian Le Alice Taubes Idit Kosti **Dmitry Rychkov** Kat Yu **Daniel Bunis** Stella Belonwu Gaia Andreoletti **Aolin Wang** Ishan Paranjpe **Bianca** Vora **Manish Paranjpe** Shan Andrews Hongtai Huang Silvia Pineda

Atul Butte Joel Dudley Alex Morgan Mohan Shenoy Grace Cho Kavita Sarin Matthew Lewis **David Fiorentino Bin Chen** Hanna Paik Julien Sage Minnie Sarwal Mei-Sze Chua Samuel So Li Ma

Reetesh Pai Silke Roedder Annie Chiang Pankaj Jay Pasricha Julien Sage Alejandro Sweet-Cordero Yadong Huang

<u>Funding Sources</u> NLM, NIA, NIAMS, NICHD, March of Dimes, PTBi, Pfizer, BWF

Tech and Admin Support: Boris Oskotsky, Edna Rodas



PREMER Precision Medicine in Rheumatology


BURROUGHS

WELLCOME

FUND 🔫







Thanks!

marina.sirota@ucsf.edu

http://sirotalab.ucsf.edu

We are hiring!